샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533816

세계의 심장 부정맥 치료제 시장

Cardiac Arrhythmias Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 183 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

심장 부정맥 치료제 시장은 2030년까지 58억 달러에 달할 전망입니다.

2023년에 48억 달러로 추정된 심장 부정맥 치료제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 2.8%를 나타낼 전망이며 2030년에는 58억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 나트륨 채널 차단제는 복합 연간 성장률(CAGR) 2.2%를 나타낼 전망이며 성장을 지속하여, 분석 기간 종료 시 18억 달러에 달할 것으로 예상됩니다. 베타 차단제 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 3.8%를 나타낼 전망입니다.

미국 시장은 13억 달러로 추정되며, 중국은 복합 연간 성장률(CAGR) 5.4%를 나타낼 전망이며 성장 예측됩니다.

미국의 심장 부정맥 치료제 시장은 2023년 13억 달러로 추정됩니다. 세계의 2위 경제대국인 중국은 2030년까지 12억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR)은 5.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 0.9%와 2.1%를 나타낼 전망이며 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 1.4%를 나타낼 전망입니다.

세계의 심장 부정맥 치료제 시장 : 주요 동향과 촉진요인 요약

심장 부정맥 치료제에는 양성인 것부터 생명을 위협하는 것까지 다양한 부정맥의 관리 및 수정을 목적으로 하는 광범위한 치료가 포함됩니다. 부정맥은 심장 박동을 조절하는 전기 신호의 장애로 인해 발생하며 심방 세동, 심실 빈맥, 서맥 등의 상태를 유발합니다. 치료 개입은 부정맥의 유형과 중증도에 따라 이루어지며 약물 치료, 생활 습관 개선, 고급 의료 절차가 포함됩니다. 심박수와 리듬을 조절하기 위해 β차단제, 칼슘 채널 차단제, 항부정맥제 등의 약제가 처방되는 경우가 많습니다. 더욱 심한 경우에는 부정맥의 원인이 되는 비정상적인 심장 조직을 파괴하는 카테터 절제나 심박을 조절하는 심박조율기나 제세동기 등의 기기의 이식 등의 처치가 이루어집니다. 이러한 치료는 삶의 질을 향상시킬 뿐만 아니라 뇌졸중과 심부전과 같은 합병증의 위험을 크게 줄입니다.

심장 부정맥 치료제의 진보는 지속적인 조사와 기술 혁신에 의해 추진되어 왔습니다. 로봇 지원 시스템과 고급 이미지 기술의 사용을 포함한 보다 정밀하고 효과적인 절제 기술의 개발로 이러한 절차의 성공률이 크게 향상되었습니다. 의료기기기술의 혁신은 원격감시와 환자의 활동 수준에 따른 자동조정 등 보다 고도의 기능을 갖춘 페이스메이커와 제세동기의 개발로 이어졌습니다. 또한, 부정맥 발생에 관여하는 특정 분자 경로를 표적으로 하는 새로운 약리학적 약제의 출현으로, 치료의 새로운 길이 열렸습니다. 임상시험에서는 이러한 새로운 치료법의 유효성과 안전성에 대한 연구가 계속되고 있으며, 부작용이 적고 보다 효과적인 부정맥 관리에 대한 기대가 높아지고 있습니다.

심장 부정맥 치료제 시장의 성장은 고령화로 인한 심혈관 질환의 유병률 증가, 라이프 스타일 변화, 부정맥 위험 인자로 알려진 고혈압 및 당뇨병과 같은 질병의 이환율 증가와 같은 몇 가지 요인에 의해 가져옵니다. 휴대용 ECG 모니터나 웨어러블 기기 등의 진단 툴의 기술적 진보로 부정맥의 조기적이고 정확한 발견이 가능해져 시기 적절한 개입이 용이해졌습니다. 소비자의 행동도 변화하고 있으며, 환자는 자신의 건강에 대해 더 적극적으로되고, 고급 치료법을 추구하고 있습니다. 또한 의료 서비스 제공업체와 지불자는 조기적이고 효과적인 부정맥 관리로 인한 장기적인 비용 이점을 점점 더 인식하게 되어 이러한 치료에 대한 보험 적용과 상환 정책 개선으로 이어졌습니다. 규제환경은 신약 및 신장치의 승인 프로세스를 가속화하는 등 기술 혁신을 더욱 뒷받침할 수 있게 되었습니다. 이러한 요인들이 결합되어 심장 부정맥 치료제 시장은 강력한 성장과 지속적인 발전을 이루며, 궁극적으로 환자의 예후를 개선하고 세계의 건강 관리 시스템에서 이러한 질병의 부담을 완화합니다.

조사 대상 기업 예(주목의 36사)

  • Abbott Cardiovascular
  • Acesion Pharma ApS
  • Baxter International Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Covis Pharma
  • Eli Lilly and Company
  • J&J MedTech
  • Mayne Pharma Group Limited
  • Medtronic
  • Novartis Pharma AG
  • Pfizer Inc
  • Roche Diagnostics Corporation
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.08.22

Global Cardiac Arrhythmias Therapeutics Market to Reach US$5.8 Billion by 2030

The global market for Cardiac Arrhythmias Therapeutics estimated at US$4.8 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Sodium-Channel Blockers, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Beta-Blockers segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.4% CAGR

The Cardiac Arrhythmias Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Cardiac Arrhythmias Therapeutics Market - Key Trends and Drivers Summarized

Cardiac arrhythmias therapeutics encompass a broad range of treatments aimed at managing and correcting irregular heartbeats, which can vary from benign to life-threatening conditions. Arrhythmias are caused by disruptions in the electrical signals that regulate the heartbeat, leading to conditions such as atrial fibrillation, ventricular tachycardia, and bradycardia. Therapeutic interventions are tailored to the type and severity of the arrhythmia and may include medications, lifestyle changes, and advanced medical procedures. Medications such as beta-blockers, calcium channel blockers, and antiarrhythmic drugs are often prescribed to control the heart rate and rhythm. For more severe cases, procedures like catheter ablation, which involves destroying the abnormal heart tissue causing the arrhythmia, or the implantation of devices like pacemakers and defibrillators to regulate heartbeats are employed. These treatments not only improve quality of life but also significantly reduce the risk of complications such as stroke and heart failure.

Advancements in cardiac arrhythmias therapeutics have been propelled by ongoing research and technological innovations. The development of more precise and effective ablation techniques, including the use of robotic-assisted systems and advanced imaging technologies, has significantly improved the success rates of these procedures. Innovations in medical device technology have led to the creation of more sophisticated pacemakers and defibrillators that offer enhanced functionality, such as remote monitoring and automatic adjustment based on the patient's activity level. Additionally, the emergence of novel pharmacological agents targeting specific molecular pathways involved in arrhythmogenesis has opened new avenues for treatment. Clinical trials continue to explore the efficacy and safety of these new therapies, offering hope for more effective management of cardiac arrhythmias with fewer side effects.

The growth in the cardiac arrhythmias therapeutics market is driven by several factors, including the increasing prevalence of cardiovascular diseases due to aging populations, lifestyle changes, and rising rates of conditions such as hypertension and diabetes, which are known risk factors for arrhythmias. Technological advancements in diagnostic tools, such as portable ECG monitors and wearable devices, have enabled earlier and more accurate detection of arrhythmias, facilitating timely intervention. Consumer behavior has also shifted, with patients becoming more proactive about their health and seeking advanced treatment options. Additionally, healthcare providers and payers are increasingly recognizing the long-term cost benefits of early and effective arrhythmia management, leading to better insurance coverage and reimbursement policies for these therapies. The regulatory environment has become more supportive of innovation, with faster approval processes for new drugs and devices. Together, these factors are ensuring robust growth and continuous advancement in the cardiac arrhythmias therapeutics market, ultimately enhancing patient outcomes and reducing the burden of these conditions on healthcare systems worldwide.

Select Competitors (Total 36 Featured) -

  • Abbott Cardiovascular
  • Acesion Pharma ApS
  • Baxter International Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Covis Pharma
  • Eli Lilly and Company
  • J&J MedTech
  • Mayne Pharma Group Limited
  • Medtronic
  • Novartis Pharma AG
  • Pfizer Inc
  • Roche Diagnostics Corporation
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Cardiac Arrhythmias Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Heart Diseases Globally Drives Demand for Arrhythmia Therapeutics
    • Advances in Pharmacological Treatments Enhance Management of Cardiac Arrhythmias
    • Technological Innovations in Cardiac Monitoring and Diagnostic Devices Lead to Increased Disease Identification & Treatment
    • Growing Awareness of Heart Health and Preventative Care Stimulates Market Growth
    • Gene- and Cell-Based Therapies Drive Market Growth
    • Role of Digital Health and Remote Monitoring in Patient Management
    • Aging Population & Risk of Arrhythmia Represent a Demographic Driver of Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cardiac Arrhythmias Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Sodium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Sodium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Sodium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Beta-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Potassium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Potassium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Potassium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Calcium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Calcium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Calcium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제